L. Deeks, S. Kosari, Anne Develin, G. Peterson, M. Naunton
{"title":"Smoking cessation and the general practice pharmacist","authors":"L. Deeks, S. Kosari, Anne Develin, G. Peterson, M. Naunton","doi":"10.1017/JSC.2019.3","DOIUrl":null,"url":null,"abstract":"Roles for pharmacists in general practice are developing in Australia. It is known that pharmacists can provide effective smoking cessation services in other settings but evidence in general practice is lacking.To determine whether a pharmacist can provide effective smoking cessation services within general practice.Data from smoking cessation consultations were obtained for 66 consecutive patients seen by one practice pharmacist. The pharmacist tailored interventions to the individual. Medication was offered in collaboration with community pharmacists and general practitioners. Quit coaching, based on motivational interviewing, was conducted. Smoking status was ascertained at least 6 months after the intended quit date and verified by a carbon monoxide breath test where possible.The patients’ median age was 43 years (range 19–74 years); 42 were females (64%). At baseline, the median (i) number of pack years smoked was 20 (range: 1–75); (ii) Fagerstrom Test of dependence score was 6 (1–10); and (iii) number of previous quit attempts was 3 (0–10). Follow-up after at least 6 months determined a self-reported point prevalence abstinence rate of 30% (20/66). Of all patients who reported to be abstinent, 65% (13/20) were tested for carbon monoxide breath levels and were all below 7 ppm. The biochemically verified smoking abstinence rate was therefore 20% overall (13/66). Successful quit attempts were associated with varenicline recommendation (69% v 25%), increased median number of practice pharmacist consultations (4 v 2 per patient) and mental health diagnosis (85% v 51%).Our observed abstinence rate was comparable or better than those obtained by practice nurses, community pharmacists and outpatient pharmacists, indicating the general practice pharmacist provided an effective smoking cessation intervention. A larger randomised trial is warranted.","PeriodicalId":39350,"journal":{"name":"Journal of Smoking Cessation","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1017/JSC.2019.3","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Smoking Cessation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1017/JSC.2019.3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 4
Abstract
Roles for pharmacists in general practice are developing in Australia. It is known that pharmacists can provide effective smoking cessation services in other settings but evidence in general practice is lacking.To determine whether a pharmacist can provide effective smoking cessation services within general practice.Data from smoking cessation consultations were obtained for 66 consecutive patients seen by one practice pharmacist. The pharmacist tailored interventions to the individual. Medication was offered in collaboration with community pharmacists and general practitioners. Quit coaching, based on motivational interviewing, was conducted. Smoking status was ascertained at least 6 months after the intended quit date and verified by a carbon monoxide breath test where possible.The patients’ median age was 43 years (range 19–74 years); 42 were females (64%). At baseline, the median (i) number of pack years smoked was 20 (range: 1–75); (ii) Fagerstrom Test of dependence score was 6 (1–10); and (iii) number of previous quit attempts was 3 (0–10). Follow-up after at least 6 months determined a self-reported point prevalence abstinence rate of 30% (20/66). Of all patients who reported to be abstinent, 65% (13/20) were tested for carbon monoxide breath levels and were all below 7 ppm. The biochemically verified smoking abstinence rate was therefore 20% overall (13/66). Successful quit attempts were associated with varenicline recommendation (69% v 25%), increased median number of practice pharmacist consultations (4 v 2 per patient) and mental health diagnosis (85% v 51%).Our observed abstinence rate was comparable or better than those obtained by practice nurses, community pharmacists and outpatient pharmacists, indicating the general practice pharmacist provided an effective smoking cessation intervention. A larger randomised trial is warranted.
在澳大利亚,药剂师在全科实践中的作用正在发展。众所周知,药剂师可以在其他环境中提供有效的戒烟服务,但缺乏一般实践中的证据。确定药剂师是否能在一般实践范围内提供有效的戒烟服务。从一名执业药剂师看到的66名连续患者的戒烟咨询中获得数据。药剂师为个人量身定制干预措施。与社区药剂师和全科医生合作提供药物。以动机性访谈为基础,进行离职辅导。在预定戒烟日期后至少6个月确定吸烟状况,并在可能的情况下通过一氧化碳呼吸测试进行验证。患者中位年龄为43岁(范围19-74岁);女性42例(64%)。在基线时,吸烟包年的中位数为20(范围:1-75);(ii) Fagerstrom依赖性检验得分为6 (1-10);(iii)以前的戒烟尝试次数为3(0-10)。至少6个月后的随访确定自我报告的点流行戒断率为30%(20/66)。在所有报告禁欲的患者中,65%(13/20)进行了一氧化碳呼吸水平测试,均低于7ppm。因此,生化验证的戒烟率总体为20%(13/66)。成功戒烟尝试与瓦伦尼克兰推荐(69% vs 25%)、执业药师咨询中位数增加(每位患者4v2)和心理健康诊断(85% vs 51%)相关。我们观察到的戒烟率与执业护士、社区药剂师和门诊药剂师的戒烟率相当或更好,表明全科药剂师提供了有效的戒烟干预。更大规模的随机试验是有必要的。